Patents Examined by Dana Shin
  • Patent number: 9862949
    Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: January 9, 2018
    Assignee: T2CURE GMBH
    Inventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
  • Patent number: 9845471
    Abstract: The present disclosure provides compositions and methods for treating or reducing the risk of pancreatic cancer by administering compounds capable of inhibiting the expression or activity of RUNX3.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: December 19, 2017
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Sunil R. Hingorani
  • Patent number: 9808480
    Abstract: A unit structure-type pharmaceutical composition includes at least one nucleic acid, such as siRNA, electrostatically bound to at least one block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charge(s) of the nucleic acid are counterbalanced, at least substantially, by the positive charge(s) of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment(s). The at least one block copolymer thereby improves the blood retention capability of the nucleic acid(s).
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: November 7, 2017
    Assignees: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYO
    Inventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato
  • Patent number: 9803200
    Abstract: A method for preventing or treating epilepsy or status epilepticus, or a brain-related disorder which is characterized by precipitation of seizures, in an individual. The method comprises the step of treating the individual with an agent that inhibits the activity of miR-134 in the individual. The agent is delivered to the brain of the individual.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: October 31, 2017
    Assignee: Royal College of Surgeons in Ireland
    Inventors: David Henshall, Eva Jimenez-Mateos
  • Patent number: 9790518
    Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to segment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: October 17, 2017
    Assignee: GRADALIS, INC.
    Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Patent number: 9758785
    Abstract: The present invention concerns methods and compositions regarding one or more microRNAs or variants thereof that are provided to an individual for a variety of medical treatments, including sensitization to cancer therapy or prevention of a cancer to become sensitized to a cancer therapy. In specific embodiments, the microRNAs include miR-520a (including at least miR-520a-3p and miR-520-5p), miR-520g, miR-520h, and functional variants thereof. In some embodiments, the cancer is ovarian cancer, and in particular embodiments, the cancer therapy is platinum-based chemotherapy.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: September 12, 2017
    Assignees: Baylor College of Medicine, University of Houston
    Inventors: Matthew L. Anderson, Claire Mach, Preethi Gunaratne
  • Patent number: 9752142
    Abstract: The present invention provides gapped oligomeric compounds comprising at least one 5?-substituted P-D-2?-deoxyribonucleoside in the gap region. Certain such gapped oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited to, nucleic acids in a cell. The oligomeric compounds provided herein have improved properties such as selectivity, potency and improved proinflammatory profile. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: September 5, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 9701727
    Abstract: The present invention relates to methods and compositions for enhancing neuronal connectivity. It is based, at least in part, on the discovery of a protein, termed “Mirta22,” that inhibits the formation of structures which create connections between neurons. It is further based, in part, on the discovery that inhibiting Mirta22 activity by short hairpin RNA was able to restore these structures. Mirta22 was discovered in experiments relating to 22q11 microdeletions, which have been linked to schizophrenia. Accordingly, the present invention provides for methods of treating schizophrenia comprising administering an agent that inhibits Mirta22 activity. It may also be used in the treatment of other disorders that would benefit from enhanced neural connectivity, including learning and memory disorders.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 11, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Joseph A. Gogos, Bin Xu, Maria Karayiorgou
  • Patent number: 9677072
    Abstract: The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, RPS2, SCNN1A, SF3A3, TAF2, TOB1 and TSC22D4.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 13, 2017
    Assignee: Georgetown University
    Inventors: Louis M. Weiner, Rochelle E. Nasto, Robert Clarke, Erica Golemis, Ilya Serebriiskii
  • Patent number: 9650679
    Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 16, 2017
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 9650680
    Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: May 16, 2017
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 9637744
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: May 2, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Laurent Gouya, Jean-Charles Deybach, Herve Puy, Vincent Oustric
  • Patent number: 9617539
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 11, 2017
    Assignees: Ionis Pharmaceuticals, Inc., Baylor College of Medicine
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • Patent number: 9617544
    Abstract: The invention provides multifunctional supramolecular self-assembled nanoparticles (SSNPs) comprising a set of rationally designed components that collectively facilitate efficient intestinal absorption of siRNA. The nanoparticles can induce potent TNF-? silencing in macrophages. Single gavage of SSNPs in mice depleted systemic TNF-? production at an siRNA dose as low as 50 ?g/kg, and protected the mice from lipopolysaccharide-induced hepatic injury.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: April 11, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Jianjun Cheng, Lichen Yin
  • Patent number: 9611472
    Abstract: The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides single-stranded small interfering RNAs. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 4, 2017
    Assignee: University of Massachusetts
    Inventors: Phillip D. Zamore, Gyorgy Hutvagner, Dianne Schwarz, Guiliang Tang, Benjamin Haley
  • Patent number: 9605266
    Abstract: Provided herein are fluoropyrimidine-modified RNA aptamers capable of binding CCR5. The compositions and methods provided herein are, inter alia, useful for the delivery of anti-viral drugs (e.g., siRNAs) and preventing HIV entry into a target cell.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: March 28, 2017
    Assignees: CITY OF HOPE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: John Rossi, Jiehua Zhou, Marc Weinberg, Kevin Morris
  • Patent number: 9551036
    Abstract: Aspects of the invention relate to methods and compositions for characterizing or modulating the expression of metabolic mesenchymal genes. In some embodiments, methods for assessing the expression of metabolic mesenchymal genes and related gene signatures are provided that are useful for cancer classification, prognosis, diagnosis, or treatment selection.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: January 24, 2017
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Yoav D. Shaul, David M. Sabatini
  • Patent number: 9550995
    Abstract: Provided is a composition for inducing tumor cell senescence and a method for inducing tumor cell senescence using the same. The composition can inhibit a PAPSS2 gene in a tumor cell to thereby induce senescence of the tumor cell, and if the composition is used concurrently with irradiation of the tumor cell, the composition can improve the sensitivity of the tumor cell to radiation.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: January 24, 2017
    Assignees: Korea Institute of Radiological & Medical Sciences, Inha University Research and Business Foundation
    Inventors: Jae-Seon Lee, Seung Hee Jung, Bong Cho Kim, Hyung Chul Lee, Na-Kyung Han, Mi-Na Hong
  • Patent number: 9540412
    Abstract: The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonucleotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: January 10, 2017
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Matthew Levy, Amy Yan, Brian Wengerter
  • Patent number: 9540649
    Abstract: The present invention is directed to a method and use of RNA interference (RNAi) for the transient, reversible and controlled opening of the tight junctions of the blood brain barrier and/or the blood retinal barrier. This method may be used in the treatment of many diseases and disorders which require the opening of the blood brain barrier and/or blood retinal barrier. Such methods generally involve the use of an RNAi-inducing agent, such as siRNA, miRNA, shRNA or an RNAi-inducing vector whose presence within a cell results in production of an siRNA or shRNA, targeting tight junction proteins to open the blood brain barrier and/or blood retinal barrier.
    Type: Grant
    Filed: October 13, 2008
    Date of Patent: January 10, 2017
    Assignee: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
    Inventors: Peter Humphries, Matthew Campbell, Anna-Sophia Kiang